… of the presence of both obesity and polypharmacy in NVAF patients, … safety of rivaroxaban
compared with warfarin in a population of NVAF patients with both obesity and polypharmacy. …

… obesity and polypharmacy in the US. We hypothesized that rivaroxaban would be an effective
and safe treatment option for NVAF patients with obesity and polypharmacy compared to …

… among NVAF patients with obesity and polypharmacy initiated on rivaroxaban or warfarin.
Eligible patients were those with ≥1 dispensing for rivaroxaban or warfarin between 4 …

… Although there is no consensus definition of polypharmacy, for the purpose of this analysis,
we considered 3 clinically relevant categories of concomitant medications and polypharmacy …

… overweight patients, while from 2018 to 2020, there was a decreasing trend in rivaroxaban
prescribing in all obese … highest mortality being among morbidly obese patients (BMI ≥ 40 kg/…

… Due to the high likelihood of polypharmacy in … safety of rivaroxaban versus warfarin in
patients with NVAF managed in routine clinical practice with varying degrees of polypharmacy. …

… In this analysis, we demonstrate that the efficacy and the safety of low-dose rivaroxaban …
did not affect the relative efficacy or safety of rivaroxaban, with the potential exception of NSAIDs…

… In another pharmacokinetic study, apixaban and rivaroxaban concentrations were assessed
in 100 obese patients having a median (range) weight and BMI of 139 (120-230) kg and 45 (…

… We included AF patients aged ≥18 years with severe obesity who received oral anticoagulation
(dabigatran, apixaban, rivaroxaban, or warfarin) between 10/01/2010 and 12/31/2019 …

… with polypharmacy, and only apixaban and rivaroxaban were associated with significantly
lower risks of intracranial bleeding compared to VKAs. Likewise, lower risks of major and …